Rapid Postoperative Relapse in ALK-Positive Locally Advanced NSCLC Patient with Complete Pathological Response to Neoadjuvant Crizotinib
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference5 articles.
1. Neoadjuvant crizotinib in resectable locally advanced non-small cell lung cancer with ALK rearrangement;Zhang;J Thorac Oncol,2019
2. Lung cancer's real adjuvant EGFR targeted therapy questions;Ng;Lancet Oncol,2018
3. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer;Chaft;Lung Cancer,2018
4. Lung cancer: current therapies and new targeted treatments;Hirsch;Lancet,2017
5. Ensartinib (X-396) in ALK-positive non-small cell lung cancer: results from a first-in-human phase I/II, multicenter study;Horn;Clin Cancer Res,2018
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A case report: Pathological complete response to neoadjuvant lorlatinib for Epithelioid inflammatory myofibroblastic sarcoma with EML4-ALK rearrangement;Frontiers in Pharmacology;2024-07-31
2. Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges;Frontiers in Oncology;2023-12-08
3. Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in ALK-positive non-small-cell lung cancer;Immunotherapy;2023-08
4. Complete pathological response and negative postoperative ctDNA were not predictive of discontinuation of adjuvant crizotinib therapy in a patient with locally advanced MET ex14 skipping mutation-positive non-small cell lung cancer: a case report;Frontiers in Oncology;2023-07-24
5. Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer;Targeted Oncology;2023-06-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3